For breast cancer or malignant melanoma. ANDA 213516, held by Jubilant. Technetium TC-99M Sulfur Colloid Kit.
As of Nov 22, 2026, ANDA 213516 (Technetium TC-99M Sulfur Colloid Kit), held by Jubilant, was first approved by FDA on Nov 9, 2023, with 0 approved supplements and 0 published complete response letters.
Technetium Tc 99m Sulfur Colloid Injection is indicated: In adults, to assist in the: Localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma when used with a hand-held gamma counter. Evaluation of peritoneo-venous (LeVeen) shunt patency. In adults and pediatric patients, for imaging: Areas of functioning reticuloendothelial cells in the liver, spleen and bone marrow. Studies of esophageal transit and gastroesophageal reflux, and detection of pulmonary aspiration of gastric contents.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 9, 2023 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Technetium TC-99M Sulfur Colloid Kitsolution;injection, oral | Technetium TC-99M Sulfur Colloid Kit | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters